Abstract
Metal ions, particularly copper, zinc and iron, are implicated in several amyloidogenic neurodegenerative disorders. In the brain, as elsewhere in the body, metal ion excess or deficiency can potentially inhibit protein function, interfere with correct protein folding or, in the case of iron or copper, promote oxidative stress. The involvement of metal ions in neurodegenerative disorders has made them an emerging target for therapeutic interventions. One approach has been to chelate and sequester the ions and thus limit their potential to interfere with protein folding or render them unable to undergo redox processes. Newer approaches suggest that redistributing metal ions has therapeutic benefits, and recent studies indicate that alleviating cellular copper deficiency may be a plausible way to limit neurodegeneration. In this review we discuss the role of metals in amyloidogenic, neurodegenerative disorders and highlight some mechanisms and compounds used in various therapeutic approaches.
Keywords: Alzheimer's, chelator, copper, iron, neurodegeneration, Parkinson's, prion, redox, Creutzfeldt-Jakob disease, oxidative stress, neurodegenerative disorders, synucleinopathies, synuclein, zinc
Current Topics in Medicinal Chemistry
Title: Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Volume: 11 Issue: 5
Author(s): Alison C. Badrick and Christopher E. Jones
Affiliation:
Keywords: Alzheimer's, chelator, copper, iron, neurodegeneration, Parkinson's, prion, redox, Creutzfeldt-Jakob disease, oxidative stress, neurodegenerative disorders, synucleinopathies, synuclein, zinc
Abstract: Metal ions, particularly copper, zinc and iron, are implicated in several amyloidogenic neurodegenerative disorders. In the brain, as elsewhere in the body, metal ion excess or deficiency can potentially inhibit protein function, interfere with correct protein folding or, in the case of iron or copper, promote oxidative stress. The involvement of metal ions in neurodegenerative disorders has made them an emerging target for therapeutic interventions. One approach has been to chelate and sequester the ions and thus limit their potential to interfere with protein folding or render them unable to undergo redox processes. Newer approaches suggest that redistributing metal ions has therapeutic benefits, and recent studies indicate that alleviating cellular copper deficiency may be a plausible way to limit neurodegeneration. In this review we discuss the role of metals in amyloidogenic, neurodegenerative disorders and highlight some mechanisms and compounds used in various therapeutic approaches.
Export Options
About this article
Cite this article as:
C. Badrick Alison and E. Jones Christopher, Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease, Current Topics in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/156802611794785181
DOI https://dx.doi.org/10.2174/156802611794785181 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NO Chimeras as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
Current Neuropharmacology Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal The Molecular Pathology of Huntingtons Disease (HD)
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Towards Retinoid Therapy for Alzheimers Disease
Current Alzheimer Research Green Synthesis of Phosphoryl-2-Oxo-2H-Pyran via Three Component Reaction of Trialkyl Phosphites
Combinatorial Chemistry & High Throughput Screening Evaluation of the Binding Affinity of a Gonadotropin-Releasing Hormone Analogue (GnRH-a) Buserelin through <i>In silico</i> and <i>In vivo</i> Testing in <i>Clarias magur</i>
Current Proteomics Dysregulation of Acetylation Enzymes Inanimal Models of Psychostimulant use Disorders: Evolving Stories
Current Neuropharmacology A Survey of Peptides with Effective Therapeutic Potential in Alzheimer’s Disease Rodent Models or in Human Clinical Studies
Mini-Reviews in Medicinal Chemistry Neuroprotective Role of Nanoparticles Against Alzheimer's Disease
Current Drug Metabolism Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Biomarkers and Cellular Signal Detection for Alzheimer’s Disease, Stroke, and Immune System Mediated Disorders
Current Neurovascular Research From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Characterization and Immunological Evaluation of Low-Molecular- Weight Alginate Derivatives
Current Topics in Medicinal Chemistry Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Current Signal Transduction Therapy The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders
Current Pharmaceutical Design New Technologies for Drug Delivery Across the Blood Brain Barrier
Current Pharmaceutical Design Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design